Galecto, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLTO research report →
Companygalecto.com
Galecto, Inc. , a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis.
- CEO
- Lori C. Firmani
- IPO
- 2020
- Employees
- 5
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $38.64M
- P/E
- -0.16
- P/S
- 0.00
- P/B
- 0.08
- EV/EBITDA
- 2.06
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -122.40%
- ROIC
- -46.73%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-209,839,000 · -878.77%
- EPS
- $-3.71 · 78.52%
- Op Income
- $-210,872,000
- FCF YoY
- 63.88%
Performance & Tape
- 52W High
- $38.33
- 52W Low
- $2.01
- 50D MA
- $26.12
- 200D MA
- $13.34
- Beta
- 1.57
- Avg Volume
- 474.92K
Get TickerSpark's AI analysis on GLTO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 9, 26 | Bruno Julianne | other | 129,000 |
| Feb 9, 26 | Bruno Julianne | other | 129 |
| Feb 9, 26 | Fairmount Funds Management LLC | other | 5,809,000 |
| Feb 9, 26 | Fairmount Funds Management LLC | other | 2,904,000 |
| Feb 9, 26 | Fairmount Funds Management LLC | other | 5,809 |
| Feb 9, 26 | Fairmount Funds Management LLC | other | 2,904 |
| Jan 5, 26 | Sattarzadeh Sherwin | other | 444,209 |
| Jan 5, 26 | Sattarzadeh Sherwin | other | 190,376 |
| Jan 5, 26 | Sattarzadeh Sherwin | other | 0 |
| Jan 5, 26 | Hewes L. Becker | other | 528,603 |
Our GLTO Coverage
We haven't published any research on GLTO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GLTO Report →